Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.
Executive Summary
The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.
You may also be interested in...
AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials
A U.S. NDA filing for AstraZeneca's combination asthma therapy Symbicort awaits completion of Phase III trials of the beta agonist (formoterol) component.
AstraZeneca Symbicort U.S. Filing Awaits Results of Formoterol Trials
A U.S. NDA filing for AstraZeneca's combination asthma therapy Symbicort awaits completion of Phase III trials of the beta agonist (formoterol) component.
AstraZeneca Reiterates Importance Of Salick To Developing Oncology
AstraZeneca continues to see long-term value in Salick Health Care from the contact that the treatment clinics provide with current trends in oncology, AstraZeneca CEO Tom McKillop, PhD, said at a 1999 earnings review Feb. 24 in London.